Daily Market Reports | Mar 10 2026
This story features ASTRAL RESOURCES NL, and other companies.
For more info SHARE ANALYSIS: AAR
The company is included in ALL-ORDS
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities.
In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Australian Broker Call *Extra* Edition, featuring additional sources of research and insights on ASX-listed stocks, also enlarging the number of stocks that make up the FNArena universe.
One key difference is the *Extra* Edition will not be updated daily, but merely “regularly” depending on availability of suitable quality content. As such, the *Extra* Edition tries to build a bridge between daily updates via the Australian Broker Call Report and ad hoc news stories, that are not always timely for investors hungry for the next information update.
Investors using the *Extra* Edition as a source of input for their own share market research should thus take into account that information after publication may not be up to date, or yet awaiting another update by FNArena’s team of journalists.
Similar to The Australian Broker Call Report, this *Extra* Edition includes concise but limited reviews of research recently published by Stockbrokers and other experts, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end of this Report.
The Australian Broker Call *Extra* Edition is a summary that has been prepared independently of the sources identified. Readers will check the full text of the recommendations and consult a Licenced Advisor before making any investment decision.
The copyright of this Report is owned by the publisher. Readers will not copy, forward or disseminate this Report to any other person. For more vital information about the sources included, see the bottom of this Report.
COMPANIES DISCUSSED IN THIS ISSUE
Click on a symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
AAR AEL AIZ AMC ART CMA CSC CTE CUV CYL EXP GOZ LNQ MAQ MHJ MM8 NEU NXD OBM PPL RWL SHJ SOM TLX TPG VGL (2) VGN
AAR ASTRAL RESOURCES NL
Gold & Silver – Overnight Price: $0.23
Canaccord Genuity rates ((AAR)) as Speculative Buy (1) –
Astral Resources has the outcome of a prefeasibility study for its Mandilla project and over the first 12 years forecasts production to average 95,000ozpa at 1.13g/t with the highest grade ore available prioritised for milling early in the mine life.
A land-use agreement has been executed covering the Feysville gold tenements including the 85,000 ounce Think Big deposit.
Canaccord Genuity notes the company continues to execute an aggressive multi-rig program across Mandilla, Feysville and Spargoville, maintaining a Speculative Buy rating and $1.10 target.
This report was published on February 27, 2026.
Target price is $1.10 Current Price is $0.23 Difference: $0.865
If AAR meets the Canaccord Genuity target it will return approximately 368% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AEL AMPLITUDE ENERGY LIMITED
Crude Oil – Overnight Price: $2.70
Jarden rates ((AEL)) as Overweight (2) –
Amplitude Energy has discovered gas at the Isabella well in the Waarre C reservoir, Jarden notes, restoring confidence in exploration across the company’s East Coast Supply Project acreage.
The well intersected 8.2 metres of high-quality net pay, below pre-drill expectations and likely closer to a low-side resource outcome.
The analysts believe the discovery remains economic and removes concerns around seismic interpretation following the nearby Elanora exploration failure.
Jarden expects testing to confirm gas volumes, pressure and composition, with a 30PJ gas sales agreement with EnergyAustralia contingent on East Coast Supply Project (ECSP) development approval.
Jarden raises its target price to $2.85 from $2.75 and retains an Overweight rating.
This report was published on March 2, 2026.
Target price is $2.85 Current Price is $2.70 Difference: $0.15
If AEL meets the Jarden target it will return approximately 6% (excluding dividends, fees and charges).
Current consensus price target is $3.23, suggesting upside of 19.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 18.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 14.59.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 21.0, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 12.9.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 30.50 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.85.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 26.9, implying annual growth of 28.1%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 10.0.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AIZ AIR NEW ZEALAND LIMITED
Transportation & Logistics – Overnight Price: $0.40
Jarden rates ((AIZ)) as Downgrade to Sell from Underweight (5) –
Jarden lowers its target for Air New Zealand to NZ47c from NZ55c and downgrades to Sell from Underweight after a worse-than-expected interim result.
The airline reported a profit before tax loss of -NZ$59m, worse than guidance of -NZ$30m to -$55m, the broker notes, reflecting higher fuel prices.
It’s noted engine maintenance issues, weak domestic demand, rising aviation charges and a weaker NZ dollar also pressured earnings.
The analysts expect a similar or slightly weaker second-half outcome, with Air New Zealand guiding to comparable earnings performance and capacity rising 3-4%.
Jarden forecasts a FY26 net loss of -NZ$134m and a FY27 loss of -NZ$60m, with profit recovery delayed until FY28 and dividends returning in FY29.
This report was published on March 2, 2026.
Current Price is $0.40. Target price not assessed.
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 4.74 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 8.44.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 2.06 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 19.46.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: -1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
AMC AMCOR PLC
Paper & Packaging – Overnight Price: $60.52
Jarden rates ((AMC)) as Overweight (2) –
In a further review of Amcor’s interim results in early-February, Jarden notes investor concerns eased after management re-affirmed Berry merger synergies. It’s felt balance sheet deleveraging via free cash flow (FCF) after dividends also helped.
The analyst expects volumes to stabilise in late-FY26 before turning positive in FY27, with core EPS of $4.02 forecast near the lower end of management’s guidance.
Jarden notes earnings and free cash flow skew heavily to the June quarter, creating execution risk amid volatile packaging demand.
This report was published on March 2, 2026.
Target price is $75.00 Current Price is $60.52 Difference: $14.48
If AMC meets the Jarden target it will return approximately 24% (excluding dividends, fees and charges).
Current consensus price target is $77.87, suggesting upside of 28.7%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 391.11 cents and EPS of 611.78 cents.
At the last closing share price the estimated dividend yield is 6.46%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.89.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 569.3, implying annual growth of N/A.
Current consensus DPS estimate is 367.5, implying a prospective dividend yield of 6.1%.
Current consensus EPS estimate suggests the PER is 10.6.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 413.94 cents and EPS of 665.04 cents.
At the last closing share price the estimated dividend yield is 6.84%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.10.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 634.1, implying annual growth of 11.4%.
Current consensus DPS estimate is 374.6, implying a prospective dividend yield of 6.2%.
Current consensus EPS estimate suggests the PER is 9.5.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
ART AIRTASKER LIMITED
Online media & mobile platforms – Overnight Price: $0.23
Research as a Service (RaaS) rates ((ART)) as No Rating (-1) –
Airtasker delivered revenue growth of 13.5% in the first half, largely in line with estimates. Research as a Service (RaaS) finds second half trends appear in keeping with the results, with management forecasting double-digit Australian revenue and increased cash flow generation as well as an accelerated trajectory in the US and UK.
Recent share price weakness is attributed to the AI disruption fears that are sweeping the market which the broker is less concerned about. Data ownership, trust and the physical work constraints are key arguments against disruption being caused by AI.
Valuation is $0.48, down from $0.51. Research as a Service (RaaS) research doesn’t carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.
This report was published on March 2, 2026.
Target price is $0.48 Current Price is $0.23 Difference: $0.25
If ART meets the Research as a Service (RaaS) target it will return approximately 109% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Research as a Service (RaaS) forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 7.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 2.99.
Forecast for FY27:
Research as a Service (RaaS) forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.40 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.43.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CMA CARMA LIMITED
Automobiles & Components – Overnight Price: $0.98
Canaccord Genuity rates ((CMA)) as Buy (1) –
Carma provided a first half result that was in line with prospectus forecasts. Canaccord Genuity notes operating momentum is strong into the second half and continues to expect GPU to scale up to around $5400 by FY28 as the company benefits from scale across sourcing, reconditioning and brand recognition.
Given the underlying momentum, the broker envisages potential upside to prospectus forecasts for FY26 revenue of $128m.
Commentary posits the company is in the early stages of disrupting the large and highly fragmented Australian used car market and the broker retains a Buy rating and $3.50 target.
This report was published on February 27, 2026.
Target price is $3.50 Current Price is $0.98 Difference: $2.52
If CMA meets the Canaccord Genuity target it will return approximately 257% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CSC CAPSTONE COPPER CORP.
Copper – Overnight Price: $11.53
Moelis rates ((CSC)) as Hold (3) –
Capstone Copper delivered a variable result in 2025, with lower sales offsetting better realised prices. Moelis finds little to read through on future earnings and makes no significant changes to its modelling, retaining a Hold rating and $14.50 target.
Commentary states the primary driver of the share price is copper with the business in good health and preconditions satisfied to fully commit to Santo Domingo when ready.
While the recent 2026 guidance appeared to disappoint some investors, the broker suspects there may have been both “fast money” exiting and some rising concern for a reversal of the recent supply tightness in copper.
This report was published on March 4, 2026.
Target price is $14.50 Current Price is $11.53 Difference: $2.97
If CSC meets the Moelis target it will return approximately 26% (excluding dividends, fees and charges).
Current consensus price target is $15.70, suggesting upside of 36.2%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 0.00 cents and EPS of 35.10 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 32.85.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 62.2, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 18.5.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 0.00 cents and EPS of 72.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 16.01.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 98.1, implying annual growth of 57.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 11.8.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.9
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CTE CRYOSITE LIMITED
Medical Equipment & Devices – Overnight Price: $1.20
Research as a Service (RaaS) rates ((CTE)) as No Rating (-1) –
Cryosite, which specialises in temperature-controlled storage and logistics for life sciences and pharmaceuticals businesses, showed an acceleration in growth in the first half. Revenue was up 24.6% and EBITDA up 32.5%.
Research as a Service (RaaS) highlighted the Ultra-Frozen and Cryogenic segment, which posted 63.1% revenue growth.
The acquisition of the new facility at Adderley Street West, Auburn has been completed and will provide critical capacity to meet growing demand.
Research as a Service (RaaS) research doesn’t carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.
This report was published on March 2, 2026.
Current Price is $1.20. Target price not assessed.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CUV CLINUVEL PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $10.00
Canaccord Genuity rates ((CUV)) as Buy (1) –
Clinuvel Pharmaceuticals’ first-half FY26 revenue missed Canaccord Genuity’s expectations by -3%, rising 4% year-on-year to $36.9m.
Revenue derived from the US declined -18% year-on-year to $19.4m amid government shutdowns and Disc Medicine trial activity, explain the analysts, while ex-US revenue rose 45%.
The broker estimates earnings (EBITDA) of $12.5m with margins easing to 34% from historically above 40%, while cash closed the half at $233m.
Revenue forecasts fall by -7-20% through the forecast period as expectations for erythropoietic protoporphyria (EPP) ease and Vitiligo approval shifts to FY29, explains the broker.
Canaccord cuts its target price to $27.90 from $32.84 and retains a Buy rating.
This report was published on February 27, 2026.
Target price is $27.90 Current Price is $10.00 Difference: $17.9
If CUV meets the Canaccord Genuity target it will return approximately 179% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 7.00 cents and EPS of 71.60 cents.
At the last closing share price the estimated dividend yield is 0.70%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.97.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 15.00 cents and EPS of 80.60 cents.
At the last closing share price the estimated dividend yield is 1.50%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 12.41.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
CYL CATALYST METALS LIMITED
Gold & Silver – Overnight Price: $6.67
Canaccord Genuity rates ((CYL)) as Buy (1) –
Catalyst Metals’ first-half FY26 result broadly matched Canaccord Genuity’s expectations.
Earnings (EBITDA) of $145m were up 92% year-on-year while profit of $60m fell short of the broker’s forecasts after a one-off -$49m legal settlement cost.
Cash and bullion totaled $238m at period end, leaving the company debt free with total liquidity of $338m including a $100m undrawn facility.
The broker highlights strong drilling results at Old Highway, confirming potential growth to the planned four-year, 35kozpa mine life.
Canaccord retains a Buy rating and target of $13.35.
This report was published on February 27, 2026.
Target price is $13.35 Current Price is $6.67 Difference: $6.68
If CYL meets the Canaccord Genuity target it will return approximately 100% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 81.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.23.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 143.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 4.66.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
EXP EXPERIENCE CO LIMITED
Travel, Leisure & Tourism – Overnight Price: $0.10
Canaccord Genuity rates ((EXP)) as Buy (1) –
Canaccord Genuity notes Experience Co’s first-half FY26 result broadly reflected prior trading updates, with weaker conditions across peak trading months due to industrial disruption, promotions and weather.
Adventure Experiences delivered revenue growth while Skydiving volumes in Australia declined, observes the broker, leaving the domestic business under strategic review.
Cash generation softened during the half, though the analyst considers the balance sheet manageable with net debt below one times earnings.
FY26 and FY27 revenue forecasts are cut by -3% and earnings forecasts by -4%, reflecting weaker recent trading. Target price falls to 16c from 18c. Buy rating retained.
This report was published on March 2, 2026.
Target price is $0.16 Current Price is $0.10 Difference: $0.06
If EXP meets the Canaccord Genuity target it will return approximately 60% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.28 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 35.71.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.75 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 13.33.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
GOZ GROWTHPOINT PROPERTIES AUSTRALIA
Infra & Property Developers – Overnight Price: $2.13
Moelis rates ((GOZ)) as Buy (1) –
Growthpoint Properties Australia grew FFO per security in the first half by 3.5% and tightened FY26 guidance to 23-23.6 cents with the distribution maintained at 18.4 cents.
Moelis lowers medium-term earnings estimates because of higher cost and more conservative assumptions on downtime and leasing capital expenditure.
Longer term, the broker envisages the prospect of tightening office markets being the key catalyst for earnings and a re-rating in the share price. Buy rating retained. Target is $2.98.
This report was published on March 3, 2026.
Target price is $2.98 Current Price is $2.13 Difference: $0.85
If GOZ meets the Moelis target it will return approximately 40% (excluding dividends, fees and charges).
Current consensus price target is $2.56, suggesting upside of 20.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 18.40 cents and EPS of 23.50 cents.
At the last closing share price the estimated dividend yield is 8.64%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.06.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 17.6, implying annual growth of N/A.
Current consensus DPS estimate is 18.4, implying a prospective dividend yield of 8.6%.
Current consensus EPS estimate suggests the PER is 12.1.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 17.80 cents and EPS of 23.00 cents.
At the last closing share price the estimated dividend yield is 8.36%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 9.26.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 17.4, implying annual growth of -1.1%.
Current consensus DPS estimate is 18.4, implying a prospective dividend yield of 8.6%.
Current consensus EPS estimate suggests the PER is 12.2.
Market Sentiment: 0.8
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
LNQ LINQ MINERALS LIMITED
Mining – Overnight Price: $0.45
Research as a Service (RaaS) rates ((LNQ)) as No Rating (-1) –
Linq Minerals, focused on development and exploration at the Gilmore project, has completed 4km of the initial 16km of proposed drilling and is expanding forward drilling to 30km after recently raising capital. The project possesses a significant copper-gold resource with close proximity to infrastructure.
Research as a Service (RaaS) highlights there is now $20m in cash which should provide the company with sufficient funding to continue progressing planned activities.
On comparable metrics the broker believes the stock is undervalued and investors do not fully appreciate the scale and economic potential of Gilmore.
Research as a Service (RaaS) research doesn’t carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.
This report was published on March 2, 2026.
Current Price is $0.45. Target price not assessed.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MAQ MACQUARIE TECHNOLOGY GROUP LIMITED
Cloud services – Overnight Price: $61.21
Canaccord Genuity rates ((MAQ)) as Buy (1) –
Macquarie Technology’s first-half FY26 earnings (EBITDA) of $57.9m modestly exceeded Canaccord Genuity’s expectation and came in slightly ahead of consensus.
The broker highlights revenue growth of 5% year-on-year, supported by double-digit expansion in Cloud Services & Government and Data Centres.
While Telecom revenue declined -8% year-on-year, strong cash conversion of 109% and solid free cash flow (FCF) generation are noted.
The FY26 earnings forecast is raised by 2% though first earnings are delayed from the IC3 Super West data centre to FY28.
Canaccord reiterates a Buy rating on Macquarie Technology with its target price unchanged at $95.
This report was published on February 27, 2026.
Target price is $95.00 Current Price is $61.21 Difference: $33.79
If MAQ meets the Canaccord Genuity target it will return approximately 55% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 105.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 58.30.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 42.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 145.74.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MHJ MICHAEL HILL INTERNATIONAL LIMITED
Luxury – Overnight Price: $0.43
Jarden rates ((MHJ)) as Overweight (2) –
Michael Hill delivered improving sales momentum across markets in the first half of FY26, Jarden notes, with same store sales rising 3.8% year-on-year.
Sales growth accelerated to 6.0% in the first eight weeks of the second half, led by particularly strong demand in Canada, explain the analysts.
The earnings (EBIT) margin improved to 8.3%, up 170bps year-on-year, supported by operating leverage and recent cost reductions despite pressure from precious metal prices, the broker highlights.
The FY26 comparable EBIT forecast is raised by 21% on stronger trading momentum, while Jarden also adopts a more conservative medium-term view on gross margin recovery.
Overweight rating maintained. Target lifted to NZ$0.80 from NZ$0.70.
This report was published on March 2, 2026.
Current Price is $0.43. Target price not assessed.
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 1.00 cents and EPS of 4.10 cents.
At the last closing share price the estimated dividend yield is 2.30%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.61.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 4.50 cents and EPS of 7.00 cents.
At the last closing share price the estimated dividend yield is 10.34%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 6.21.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
MM8 MEDALLION METAL LIMITED
Gold & Silver – Overnight Price: $0.39
Canaccord Genuity rates ((MM8)) as Speculative Buy (1) –
Medallion Metals has advanced the development of its Ravensthorpe Gold Project, with Canaccord Genuity highlighting feasibility study outcomes supporting a positive final investment decision (FID).
The broker notes planned production of around 77koz gold equivalent annually at costs (AISC) of -$2,279/oz across an initial 5.7-year mine life.
One of the world’s largest commodity trading companies, Trafigura, has provided a US$50m prepayment facility and offtake agreement, which the analyst considers a significant de-risking milestone for project funding.
Total pre-production capital is estimated at $138m, with liquidity of about $151m including cash, recent equity raising and available debt.
Canaccord cuts its target price to 95c from $1.05 and retains a Speculative Buy rating.
This report was published on February 27, 2026.
Target price is $0.95 Current Price is $0.39 Difference: $0.56
If MM8 meets the Canaccord Genuity target it will return approximately 144% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 39.00.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
NEU NEUREN PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $11.68
Canaccord Genuity rates ((NEU)) as Buy (1) –
Neuren Pharmaceuticals enjoyed a strong finish to Daybue sales in 2025 and Canaccord Genuity finds 2026 guidance “compelling”, implying $70-77m in royalty revenue. This despite Daybue unlikely to receive EU approval this year.
Daybue STIX will only be fully released from mid year and, alongside ongoing activation in community settings, the cadence at which the 400 patient target for treatment can occur is likely to dictate the company reaching top end of guidance, in the broker’s view.
Buy rating retained. Target rises to $24.35 from $23.00.
This report was published on February 27, 2026.
Target price is $24.35 Current Price is $11.68 Difference: $12.67
If NEU meets the Canaccord Genuity target it will return approximately 108% (excluding dividends, fees and charges).
Current consensus price target is $23.87, suggesting upside of 104.3%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 27.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 43.26.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 9.3, implying annual growth of -60.8%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 125.6.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 56.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 20.86.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 37.3, implying annual growth of 301.1%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 31.3.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
NXD NEXTED GROUP LIMITED
Education & Tuition – Overnight Price: $0.17
Canaccord Genuity rates ((NXD)) as Buy (1) –
NextEd Group provided a “solid” first half, Canaccord Genuity asserts, with revenue in line and EBITDA ahead of estimates.
Market share has increased amid a tough operating backdrop as management pushes harder into vocational and higher education verticals, the broker notes.
Buy rating maintained as there are several potential organic growth and consolidation opportunities. Target is unchanged at $0.35.
This report was published on March 2, 2026.
Target price is $0.35 Current Price is $0.17 Difference: $0.185
If NXD meets the Canaccord Genuity target it will return approximately 112% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 2.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 8.25.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus 1.00 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 16.50.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
OBM ORA BANDA MINING LIMITED
Gold & Silver – Overnight Price: $1.22
Canaccord Genuity rates ((OBM)) as Buy (1) –
Canaccord Genuity highlights the fact Ora Banda Mining finished the first half with cash of $155m and no debt, with liquidity of $205m. EBITDA of $173m exceeded the broker’s estimates.
Production guidance of 140-150,000 ounces at AISC of $3250-3350/oz for FY26 has been retained. Buy rating and $1.60 target unchanged.
This report was published on February 27, 2026.
Target price is $1.60 Current Price is $1.22 Difference: $0.385
If OBM meets the Canaccord Genuity target it will return approximately 32% (excluding dividends, fees and charges).
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
PPL PUREPROFILE LIMITED
Software & Services – Overnight Price: $0.04
Research as a Service (RaaS) rates ((PPL)) as No Rating (-1) –
Pureprofile has reiterated FY26 guidance for revenue in the range of $64-65m and an EBITDA margin of 10-11%, which was well flagged.
Research as a Service (RaaS) makes small changes to forecasts having previously incorporated the Crnrstone acquisition.
The company is reviewing its options regarding the $2.62m debt facility ahead of maturity in November. The broker expects continued strong revenue growth and a sustained return to profitability with further evidence of margin expansion to underpin the share price.
Valuation of $0.12 is unchanged. Research as a Service (RaaS) research doesn’t carry any targets, ratings or recommendations. Investors can draw conclusions from valuations and commentary.
This report was published on March 2, 2026.
Target price is $0.12 Current Price is $0.04 Difference: $0.081
If PPL meets the Research as a Service (RaaS) target it will return approximately 208% (excluding dividends, fees and charges).
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
RWL RUBICON WATER LIMITED
Industrial Sector Contractors & Engineers – Overnight Price: $0.18
Canaccord Genuity rates ((RWL)) as Buy (1) –
Rubicon Water disappointed Canaccord Genuity with its first half result as there was a significant miss on revenue and gross margin. The trends remain encouraging and the broker’s revised forecasts imply positive EBITDA in the second half.
Going forward, demand is expected to grow for sustainable water management solutions with the company offering unique and integrated products that are well placed to cater to demand, commentary concludes.
Buy rating retained. Target is reduced to $0.33 from $0.44.
This report was published on February 27, 2026.
Target price is $0.33 Current Price is $0.18 Difference: $0.15
If RWL meets the Canaccord Genuity target it will return approximately 83% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus 0.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is minus 60.00.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 0.00 cents.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SHJ SHINE JUSTICE LIMITED
Legal – Overnight Price: $0.71
Moelis rates ((SHJ)) as Buy (1) –
Shine Justice delivered “steady” earnings growth in the first half, Moelis notes, with EBITDA ahead of expectations. The broker expects the second half will feature delayed class action settlements convert to cash, with $8.5m of a potential $17.6m already received in January.
Management is targeting margin expansion over the next 24-36 months as AI, automation and data platforms move from pilot to scaled deployment. Buy rating retained. Target is reduced to $0.95 from $0.98.
This report was published on March 3, 2026.
Target price is $0.95 Current Price is $0.71 Difference: $0.24
If SHJ meets the Moelis target it will return approximately 34% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Moelis forecasts a full year FY26 dividend of 3.50 cents and EPS of 7.10 cents.
At the last closing share price the estimated dividend yield is 4.93%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 10.00.
Forecast for FY27:
Moelis forecasts a full year FY27 dividend of 4.80 cents and EPS of 7.90 cents.
At the last closing share price the estimated dividend yield is 6.76%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 8.99.
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
SOM SOMNOMED LIMITED
Medical Equipment & Devices – Overnight Price: $0.65
Canaccord Genuity rates ((SOM)) as Buy (1) –
SomnoMed delivered first half results that were in line with expectations and management has maintained FY26 guidance.
Canaccord Genuity points out the FY25 result marked a transition to sustainable earnings growth and, if the behaviour of CPAP manufacturers is any guide, the sleep industry expects a step change in volumes amid tech generated and GLP-1 associated demand.
Commentary suggests the company may already be experiencing passive upside from both trends.
The monitoring components of RA have already been cleared by the FDA and this could mean the company becomes more active in this channel. Buy rating and $1 target unchanged.
This report was published on March 2, 2026.
Target price is $1.00 Current Price is $0.65 Difference: $0.35
If SOM meets the Canaccord Genuity target it will return approximately 54% (excluding dividends, fees and charges).
The company’s fiscal year ends in June.
Forecast for FY26:
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.20 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 54.17.
Forecast for FY27:
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 1.70 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 38.24.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TLX TELIX PHARMACEUTICALS LIMITED
Pharmaceuticals & Biotech/Lifesciences – Overnight Price: $10.20
Canaccord Genuity rates ((TLX)) as Buy (1) –
Telix Pharmaceuticals, having confidently delivered 2026 guidance for up to 25% growth in PSMA portfolio sales, has received a “response” from competitor Lantheus in terms of its sales guidance, Canaccord Genuity notes.
Outside of this quasi-duopoly in PSMA the broker envisages limited competitive threats over the medium term.
The European market is expected to stay fragmented and at this stage Telix and Curium are the only companies showing an interest in coordinating PSMA supply in that region. Buy rating and $28.50 target.
This report was published on February 27, 2026.
Target price is $28.50 Current Price is $10.20 Difference: $18.3
If TLX meets the Canaccord Genuity target it will return approximately 179% (excluding dividends, fees and charges).
Current consensus price target is $24.55, suggesting upside of 140.7%(ex-dividends)
Forecast for FY26:
Current consensus EPS estimate is -10.6, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is N/A.
Forecast for FY27:
Current consensus EPS estimate is 19.6, implying annual growth of N/A.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 52.0.
This company reports in USD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
TPG TPG TELECOM LIMITED
Telecommunication – Overnight Price: $3.91
Jarden rates ((TPG)) as Overweight (2) –
TPG Telecom delivered EBITDA in 2025 that was in line with guidance, supported by mobile revenue growth and costs control.
Jarden notes capital intensity is declining and mobile service revenue remains a primary earnings driver into 2026 with both subscriber and revenue per unit dynamics supportive.
The broker considers the stock a more capital-light and dependable cash flow generator although with the register still reliant on dividends. Overweight retained. Target is steady $3.95.
This report was published on February 28, 2026.
Target price is $3.95 Current Price is $3.91 Difference: $0.04
If TPG meets the Jarden target it will return approximately 1% (excluding dividends, fees and charges).
Current consensus price target is $4.04, suggesting upside of 3.3%(ex-dividends)
The company’s fiscal year ends in December.
Forecast for FY26:
Jarden forecasts a full year FY26 EPS of 7.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 50.13.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 9.1, implying annual growth of 31.7%.
Current consensus DPS estimate is 19.0, implying a prospective dividend yield of 4.9%.
Current consensus EPS estimate suggests the PER is 43.0.
Forecast for FY27:
Jarden forecasts a full year FY27 EPS of 10.80 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 36.20.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 11.2, implying annual growth of 23.1%.
Current consensus DPS estimate is 20.0, implying a prospective dividend yield of 5.1%.
Current consensus EPS estimate suggests the PER is 34.9.
Market Sentiment: 0.2
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
VGL VISTA GROUP INTERNATIONAL LIMITED
Software & Services – Overnight Price: $1.54
Canaccord Genuity rates ((VGL)) as Buy (1) –
Vista International delivered a 2025 result that slightly missed expectations although Canaccord Genuity notes SaaS revenue growth accelerated to 25% and now represents around 42% of revenue.
The broker points out the company has converted strong customer demand with an acceleration in cloud migrations, finishing with 724 live sites on Vista Cloud and 833 live sites on Digital Solutions.
Amid broader fears around AI disruption, Canaccord Genuity believes the company’s competitive mode is anchored across several facets including an embedded mission-critical system of record for global cinema chains and a vertically integrated platform.
Buy rating. Target is $4.00 (NZ$4.40).
This report was published on February 27, 2026.
Target price is $4.00 Current Price is $1.54 Difference: $2.455
If VGL meets the Canaccord Genuity target it will return approximately 159% (excluding dividends, fees and charges).
Forecast for FY26:
Forecast for FY27:
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Jarden rates ((VGL)) as Overweight (2) –
Vista International delivered a 2025 result that was largely in line with forecasts. Jarden notes revenue growth of 10% with operating leverage as EBITDA margins expanded by 280 basis points.
Maiden 2026 guidance is consistent with expectations with revenue expected to grow 9% at the mid point. The broker makes slight negative changes to earnings estimates for the short term with its long-term outlook intact.
Target is reduced to NZ$3.35 from NZ$3.50 and an Overweight rating is maintained.
This report was published on February 27, 2026.
Current Price is $1.54. Target price not assessed.
The company’s fiscal year ends in December.
Forecast for FY26:
Jarden forecasts a full year FY26 EPS of 3.04 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 50.84.
Forecast for FY27:
Jarden forecasts a full year FY27 EPS of 4.65 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 33.25.
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
VGN VIRGIN AUSTRALIA HOLDINGS LIMITED
Transportation & Logistics – Overnight Price: $2.74
Jarden rates ((VGN)) as Upgrade to Buy from Overweight (1) –
Jarden was impressed with the first half result from Virgin Australia amid lower depreciation and with the timing of capital expenditure skewed more heavily to the second half.
Commentary identifies the highlight in the strong RASK performance, largely driven by yield improvements.
The outlook appears to offer more of the same, with the broker noting execution is running to plan.
Given the recent pull back in the share price since initiating coverage, Jarden upgrades to Buy from Overweight while keeping its target at $4.
This report was published on February 28, 2026.
Target price is $4.00 Current Price is $2.74 Difference: $1.26
If VGN meets the Jarden target it will return approximately 46% (excluding dividends, fees and charges).
Current consensus price target is $3.95, suggesting upside of 44.2%(ex-dividends)
The company’s fiscal year ends in June.
Forecast for FY26:
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 50.30 cents.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5.45.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 49.2, implying annual growth of -24.7%.
Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A.
Current consensus EPS estimate suggests the PER is 5.6.
Forecast for FY27:
Jarden forecasts a full year FY27 dividend of 10.90 cents and EPS of 53.30 cents.
At the last closing share price the estimated dividend yield is 3.98%.
At the last closing share price the stock’s estimated Price to Earnings Ratio (PER) is 5.14.How do these forecasts compare to market consensus projections?
Current consensus EPS estimate is 53.1, implying annual growth of 7.9%.
Current consensus DPS estimate is 5.7, implying a prospective dividend yield of 2.1%.
Current consensus EPS estimate suggests the PER is 5.2.
Market Sentiment: 0.7
All consensus data are updated until yesterday. FNArena’s consensus calculations require a minimum of three sources
Disclaimer:
The content of this information does in no way reflect the opinions of FNArena, or of its journalists. In fact we don’t have any opinion about the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe and comment on. By doing so we believe we provide experienced, intelligent investors with a valuable tool that helps them in making up their own minds, reading market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. FNArena employs very experienced journalists who base their work on information believed to be reliable and accurate, though no guarantee is given that the daily report is accurate or complete. Investors should contact their personal adviser before making any investment decision.
Click to view our Glossary of Financial Terms
CHARTS
For more info SHARE ANALYSIS: AAR - ASTRAL RESOURCES NL
For more info SHARE ANALYSIS: AEL - AMPLITUDE ENERGY LIMITED
For more info SHARE ANALYSIS: AIZ - AIR NEW ZEALAND LIMITED
For more info SHARE ANALYSIS: AMC - AMCOR PLC
For more info SHARE ANALYSIS: ART - AIRTASKER LIMITED
For more info SHARE ANALYSIS: CMA - CARMA LIMITED
For more info SHARE ANALYSIS: CSC - CAPSTONE COPPER CORP.
For more info SHARE ANALYSIS: CTE - CRYOSITE LIMITED
For more info SHARE ANALYSIS: CUV - CLINUVEL PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: CYL - CATALYST METALS LIMITED
For more info SHARE ANALYSIS: EXP - EXPERIENCE CO LIMITED
For more info SHARE ANALYSIS: GOZ - GROWTHPOINT PROPERTIES AUSTRALIA
For more info SHARE ANALYSIS: LNQ - LINQ MINERALS LIMITED
For more info SHARE ANALYSIS: MAQ - MACQUARIE TECHNOLOGY GROUP LIMITED
For more info SHARE ANALYSIS: MHJ - MICHAEL HILL INTERNATIONAL LIMITED
For more info SHARE ANALYSIS: MM8 - MEDALLION METAL LIMITED
For more info SHARE ANALYSIS: NEU - NEUREN PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: NXD - NEXTED GROUP LIMITED
For more info SHARE ANALYSIS: OBM - ORA BANDA MINING LIMITED
For more info SHARE ANALYSIS: PPL - PUREPROFILE LIMITED
For more info SHARE ANALYSIS: RWL - RUBICON WATER LIMITED
For more info SHARE ANALYSIS: SHJ - SHINE JUSTICE LIMITED
For more info SHARE ANALYSIS: SOM - SOMNOMED LIMITED
For more info SHARE ANALYSIS: TLX - TELIX PHARMACEUTICALS LIMITED
For more info SHARE ANALYSIS: TPG - TPG TELECOM LIMITED
For more info SHARE ANALYSIS: VGL - VISTA GROUP INTERNATIONAL LIMITED
For more info SHARE ANALYSIS: VGN - VIRGIN AUSTRALIA HOLDINGS LIMITED